Cargando…
Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems
BACKGROUND: “Biomarker-driven targeted therapy,” the practice of tailoring patients’ treatment to the expression/activity levels of disease-specific genes/proteins, remains challenging. For example, while the anti-ERBB2 monoclonal antibody, trastuzumab, was first developed using well-characterized,...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784390/ https://www.ncbi.nlm.nih.gov/pubmed/26955870 http://dx.doi.org/10.1186/s12885-016-2232-2 |